Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Free Cash Flow for 6 consecutive years, with -$32.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 31.73% to -$32.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$150.8 million through Dec 2025, up 7.4% year-over-year, with the annual reading at -$150.8 million for FY2025, 7.4% up from the prior year.
  • Free Cash Flow hit -$32.6 million in Q4 2025 for Lyell Immunopharma, down from -$29.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $12.7 million in Q3 2021 to a low of -$93.3 million in Q4 2021.
  • Historically, Free Cash Flow has averaged -$43.3 million across 5 years, with a median of -$41.4 million in 2023.
  • Biggest five-year swings in Free Cash Flow: surged 148.69% in 2021 and later tumbled 518.82% in 2022.
  • Year by year, Free Cash Flow stood at -$93.3 million in 2021, then skyrocketed by 51.92% to -$44.8 million in 2022, then rose by 9.34% to -$40.7 million in 2023, then decreased by 17.27% to -$47.7 million in 2024, then surged by 31.73% to -$32.6 million in 2025.
  • Business Quant data shows Free Cash Flow for LYEL at -$32.6 million in Q4 2025, -$29.0 million in Q3 2025, and -$34.2 million in Q2 2025.